Edition:
India

People: TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

2.66USD
1:30am IST
Change (% chg)

$0.22 (+9.02%)
Prev Close
$2.44
Open
$2.44
Day's High
$2.67
Day's Low
$2.41
Volume
888,274
Avg. Vol
883,084
52-wk High
$7.34
52-wk Low
$2.21

Donegan, Michael 

Mr. Michael Donegan is Vice President - Finance of the TherapeuticsMD Inc. since April 2013. He has served as Vice President – Finance of our company since April 2013. Mr. Donegan has a 28-year background in accounting and finance. From August 2012 to April 2013, Mr. Donegan served as an independent consultant exclusively for our company, where he conceptualized, designed and executed our Sarbanes-Oxley 404 compliance program. From August 2007 to August 2012, Mr. Donegan served as an independent consultant designing and implementing Sarbanes-Oxley 404 compliance programs for various non-accelerated filers and executed on pre-designed Sarbanes-Oxley 404 compliance programs for certain large accelerated filers. From January 2005 to August 2007, Mr. Donegan served as an independent consultant exclusively for Tyco International, where he enhanced and executed the Sarbanes-Oxley 404 compliance model with their corporate headquarters group. From November 2001 to December 2004, Mr. Donegan was Manager of Financial Systems at Tyco International at its global headquarters. From 1994 to 2001, Mr. Donegan held various positions in the global consolidation/SEC reporting group at Sensormatic Electronics Corporation culminating with the acquisition of Sensormatic Electronics Corporation by Tyco International in the fall of 2001 when he was the Manager of Financial Systems. Mr. Donegan began his career at Ernst & Young, LLP where he worked in both the audit and tax departments. Mr. Donegan earned his B.S. in Accounting and his Master of Accounting from the University of Florida.

Basic Compensation

Total Annual Compensation, USD 308,125
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 395,355
Fiscal Year Total, USD 703,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tommy Thompson

378,308

John Milligan

1,701,430

Robert Finizio

2,724,580

Brian Bernick

1,297,940

Daniel Cartwright

1,245,480

Michael Donegan

703,480
As Of  31 Dec 2018